We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Electrochemical Device Identifies People at Higher Risk for Osteoporosis Using Single Blood Drop

By LabMedica International staff writers
Posted on 15 Aug 2023
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)
Image: A new electrochemical device can quickly and inexpensively identify people at greatest risk for osteoporosis (Photo courtesy of ACS Central Science, 2023)

With the global increase in life expectancy, the incidence of age-related conditions like osteoporosis is increasing. Osteoporosis, affecting around 200 million individuals worldwide, has a higher incidence among women. The multifaceted nature of osteoporosis, influenced by both genetic and environmental factors, increases the risk of bone fractures. Early intervention is vital to reduce the consequences of osteoporosis, yet current diagnostic techniques fall short of enabling early detection of this ailment. Now, researchers have developed a biosensor with the potential to identify those at the highest risk of osteoporosis, using less than a drop of blood.

Dual-energy X-ray absorptiometry, the prevalent method to assess changes in bone mineral density, is not sensitive enough to detect density loss until considerable damage has already been done. A number of genomic studies have found specific genetic variations, referred to as single nucleotide polymorphisms (SNPs), which correlate with a higher osteoporosis risk. Building upon these findings, a research team from Universitat Rovira i Virgili (Tarragona, Spain) set out to create a portable electrochemical device to rapidly detect five such SNPs in finger-prick blood samples, enabling early diagnosis of osteoporosis.

Central to the device is an electrode array housing DNA fragments corresponding to each SNP. The application of lysed whole blood to the array facilitates the binding of any matching DNA sequences with the SNPs. Amplification takes place with the incorporation of ferrocene-labeled recombinase polymerase, facilitating electrochemical detection. This innovative platform enabled the identification of osteoporosis-associated SNPs in 15 human blood samples, with validation successfully done against alternative methods. Elimination of the need to extract DNA from the blood streamlines the analysis, making it rapid (approximately 15 minutes) and cost-effective (less than $0.5 per SNP).

In addition to its rapid results and affordability, the device offers portability and ready accessibility, making it ideally suited for point-of-care scenarios instead of being confined to centralized laboratories. The technology's versatility extends its ability to be adapted for the detection of other SNPs, as demonstrated previously by the researchers in identifying drug resistance in Tuberculosis mycobacterium from sputum and predicting cardiomyopathy risk from blood samples. Although the device does not directly diagnose osteoporosis, it has the potential to assist physicians in identifying individuals who require closer monitoring for the condition.

Related Links:
Universitat Rovira i Virgili

Gold Member
Hybrid Pipette
SWITCH
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Capillary Blood Collection Tube
IMPROMINI M3
Alcohol Testing Device
Dräger Alcotest 7000

Channels

Molecular Diagnostics

view channel
Image: The diagnostic device can tell how deadly brain tumors respond to treatment from a simple blood test (Photo courtesy of UQ)

Diagnostic Device Predicts Treatment Response for Brain Tumors Via Blood Test

Glioblastoma is one of the deadliest forms of brain cancer, largely because doctors have no reliable way to determine whether treatments are working in real time. Assessing therapeutic response currently... Read more

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more